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The most active vitamin D metabolite, 1 ,25-dihydroxyvitamin D3 (1,25(OH)2D3), is a 
pleiotropic hormone with wide regulatory actions. Classically, vitamin D deficiency was 
known to alter calcium and phosphate metabolism and bone biology. In addition, recent 
epidemiological and experimental studies support the association of vitamin D deficiency 
with a large variety of human diseases, and particularly with the high risk of colorectal cancer. 
By regulating the expression of many genes via several mechanisms, 1,25(OH)2D3 induces 
differentiation, controls the detoxification metabolism and cell phenotype, sensitizes cells to 
apoptosis, and inhibits the proliferation of cultured human colon carcinoma cells. 
Consistently, 1,25(OH)2D3 and several of its analogues decrease intestinal tumourigenesis in 
animal models. Molecular, genetic, and clinical data in humans are scarce but they suggest 
that vitamin D is protective against colon cancer. Clearly, the available evidence warrants 
new, well-designed, large-scale trials to clarify the role of vitamin D in the prevention and/or 
therapy of this important neoplasia. 
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The vitamin D system 
Vitamin D belongs to a group of steroids with a broken ring known as secosteroids. The most 
important forms of vitamin D are vitamin D3 (cholecalciferol), produced in the human skin, 
and vitamin D2 (ergocalciferol), derived from plants (Horst et al. 2005). Nowadays, vitamin 
D3 is not categorized as a vitamin, but rather as a prohormone, given its synthesis in the skin 
and the multiple systemic actions of its metabolites. 
The most active metabolite of vitamin D3, 1 ,25-dihydroxyvitamin D3 (1,25(OH)2D3, 
calcitriol), is synthesized in a highly regulated multistep process. When human skin is 
exposed to sunlight, UV-B irradiation causes the photolysis of provitamin D3 (7-
dehydrocholesterol) to previtamin D3, a thermodynamically unstable isomer that is rapidly 
converted into vitamin D3. This passes into the bloodstream and is transported to the liver 
bound to the vitamin D binding protein (DBP, encoded by the GC gene) and, to a lesser 
extent, to albumin. Alternatively, vitamin D3 can be absorbed in the intestine from dietary 
sources (Holick 2005; Norman 2008). Vitamin D3 is first hydroxylated in the liver by several 
mitochondrial and microsomal vitamin D3-25-hydroxylases. The resultant 25-hydroxyvitamin 
D3 (25(OH)D3, calcidiol) is the main circulating form of vitamin D3, and it is further 
hydroxylated in the kidney by mitochondrial 25(OH)D3-1 -hydroxylase (encoded by the gene 
CYP27B1), yielding the hormonally active form 1,25(OH)2D3 (Lamprecht and Lipkin 2003; 
Deeb et al. 2007). Importantly, CYP27B1 is also expressed in other human tissues and cell 
types, such as colon, brain, prostate, endothelial and immune cells, suggesting an extra-renal 
production of 1,25(OH)2D3 with paracrine/autocrine action (Townsend et al. 2005; Norman 
2008; Norman and Bouillon 2010). The rate-limiting step in vitamin D3 metabolism is the 
transformation of 25(OH)D3 and 1,25(OH)2D3 to the less active compounds 24,25(OH)2D3 
and 1,24,25(OH)3D3, respectively, through 24-hydroxylation by the ubiquitous CYP24A1 
enzyme (Deeb et al. 2007). 
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Mechanism of action of 1 ,25-dihydroxyvitamin D3 
1,25(OH)2D3 exerts its biological effects by binding to the vitamin D receptor (VDR), which 
is a member of the nuclear receptor superfamily of transcription factors and regulates gene 
expression in a ligand-dependent manner (Deeb et al. 2007; Thorne and Campbell 2008; Kim 
et al. 2009; Wu and Zhang 2009). VDR dimerizes with another member of the same family, 
the retinoid X receptor (RXR), whose ligand is 9-cis-retinoic acid or, at least in the mouse 
brain, docosahexaenoic acid (Heyman et al. 1992; Levin et al. 1992; de Urquiza et al. 2000). 
The VDR-RXR heterodimer binds to specific sequences of its target genes termed vitamin D 
response elements (VDREs). Curiously, studies on a few genes indicate a variable effect 
(additive, synergistic, or none) of 9-cis-retinoic acid on the action of 1,25(OH)2D3. Results 
from gel-shift and transactivation assays using DNA fragments close to transcription start 
sites (TSS) suggested that VDREs usually comprise two hexanucleotide direct repeats 
separated by three or four nucleotides (AGTTCAnnnAGTTCA, being n any nucleotide; DR3 
or DR4) or two everted repeats interspaced by six to nine nucleotides 
(TGAACTnnnnnnAGTTCA; ER6-ER9) (Carlberg and Dunlop 2006; Carlberg and Seuter 
2009). 
However, this setting appears to be more complex in the light of the three chromatin 
immunoprecipitation sequencing (ChIP-Seq) studies published so far using human Epstein-
Barr virus-transformed lymphoblastoid, THP-1 monocytic leukemia, and LS180 colon cancer 
cells (Ramagalopagan et al, 2010; Heikkinen et al., 2011; Meyer et al., 2012). Although 
performed in different cell types and using different duration and dose of 1,25(OH)2D3 
treatment, these genome-wide studies coincide in concluding that there are hundreds (623, 
520, or 262, depending on the study) of genomic VDR binding sites in the absence of 
1,25(OH)2D3, which increase to thousands (2,776, 1,820 or 2,209) after 1,25(OH)2D3 
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treatment. As expected due to the different conditions analyzed, only a few of the identified 
VDR binding sites overlap in the three studies (see also Carlberg et al., 2011). Common 
findings were also the presence of most VDR binding sites far from the TSS, the preference 
for the DR3-type in those located close to the TSS, and the shift from non-DR3 type to DR3-
type upon ligand activation (Carlberg et al., 2011; Meyer et al, 2012). These studies revealed 
that though the DR3-type is the most common VDR binding site, it represents less than 30% 
of all peaks, and that a high proportion of the peaks do not contain any classical VDRE. Very 
few genes have only one VDR binding site: more complex scenarios are common, such as 
genes with multiple VDR binding sites, two closely located target genes sharing one or more 
VDR binding sites, or even clusters of target genes, each containing each of them multiple 
VDR binding sites (Carlberg et al., 2011). In line with previous data, in LS180 cells RXR co-
occupied a high proportion of VDR binding sites, which were most commonly of the DR3-
type (Meyer et al., 2012). Curiously, in this system, 1,073 (out of 1,674) 1,25(OH)2D3-
induced VDR/RXR binding sites are located within repetitive DNA (Long Interdispersed 
Nuclear Elements, LINE) (Meyer et al., 2012). The characterization of the functional 
relevance of data from ChIP-Seq studies will require the combination with transcriptomic 
results and subsequent validation analyses. 
The prevailing model for the mechanism of action of 1,25(OH)2D3/VDR predicts that, 
similarly to thyroid hormone and its receptors, in the absence of 1,25(OH)2D3 the VDR-RXR 
heterodimer is bound to VDREs and to transcriptional corepressors, such as nuclear 
corepressors (NCoRs) and the silencing mediator of retinoid and thyroid hormone receptors 
(SMRT), that recruit complexes with histone deacetylase (HDAC) activity and maintain the 
chromatin in a transcriptionally repressed state. In this model, 1,25(OH)2D3 binding to VDR 
induces conformational changes in VDR that cause the release of corepressors and binding of 
co-activators, such as steroid receptor co-activators (SRCs) and the CBP-p300 coregulator, 
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and chromatin remodelers such as switch-sucrose non-fermenting (SWI-SNF), that acetylate 
nucleosome histones to untie DNA for transcription. Once the chromatin is derepressed, 
binding of the VDR-interacting protein 205 (DRIP205) to the VDR attracts other components 
of the DRIP-TRIP complex, which acts as a bridge with RNA polymerase II and the 
transcriptional machinery, thus permitting the initiation of transcription (Haussler et al. 1998; 
Deeb et al. 2007; Carlberg and Seuter, 2009; Pike and Meyer 2010). 
The mechanism by which 1,25(OH)2D3 represses gene expression is less understood, 
although this process is probably equally important for its action, as around one-third of the 
target genes are inhibited (Pálmer et al. 2003; Heikkinen et al 2011). Several possibilities 
have been proposed, such as direct VDRE-dependent repression, competition for DNA 
binding between VDR and other transcription factors, or indirect repression via intermediate 
proteins (Kato et al. 2007; Kouzmenko et al. libro holick 2011). The best characterized 
transcriptional repression mechanism was elucidated for the CYP27B1 gene. In this case, the 
VDR-RXR heterodimer represses gene transcription in a 1,25(OH)2D3-dependent manner 
through E-box-type negative VDREs (nVDREs: CANNTG). When bound to nVDREs, the 
VDR-interacting repressor (VDIR, also known as TCF3 or E47) induces the transcriptional 
activation of the CYP27B1 gene. However, upon ligand binding VDR interacts with VDIR, 
promoting the dissociation of co-activators and the recruitment of corepressors and complexes 
with HDAC activity, which results in gene repression (Murayama et al. 2004; Kouzmenko et 
al. libro holick 2011). 
Nongenomic actions of 1,25(OH)2D3 have also been described. They are rapid and 
transcription-independent effects that include the opening of ion channels and the activation 
or inhibition of kinases, phosphatases and phospholipases, and are probably relevant for the 
biological effects of 1,25(OH)2D3 (Norman et al. 2004 Nat Rev Drug Discovery; Haussler et 
al. 2011). Thus, in SW480-ADH colon cancer cells and in other cell types, 1,25(OH)2D3 
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causes a rapid increase in the cytosolic calcium concentration followed by the transient 
activation of the RhoA small GTPase, its effector ROCK and the p38MAPK and MSK-1 
kinases that is required for the induction of its target genes (Ordóñez-Morán et al., 2008; 
Ordóñez-Morán et al., 2010). This shows the convergence of nongenomic and genomic 
1,25(OH)2D3 effects, at least in this system (Ordóñez-Morán and Muñoz 2009).  
 
1 ,25-dihydroxyvitamin D3 is a pleiotropic hormone 
The most widely and classically accepted physiological role for vitamin D, mediated mostly 
by 1,25(OH)2D3, is the regulation of calcium and phosphate homeostasis and bone 
mineralization (Holick 2007; Verstuyf et al. 2010). 1,25(OH)2D3 enhances intestinal calcium 
absorption in the small intestine and affects the absorption of dietary phosphate possibly by 
increasing its influx through the enterocyte brush border membrane (Ajibade et al. 2010). In 
concert with these effects, 1,25(OH)2D3 induces the maturation of preosteoclasts into 
osteoclasts, which remove calcium and phosphate from bone (Holick 2007; Verstuyf et al. 
2010).  
In the past decades, evidence has emerged that the importance of 1,25(OH)2D3 for health 
extends far beyond bone. The discovery in 1981 that 1,25(OH)2D3 induces the differentiation 
of myeloid leukemia cells and inhibits the growth of melanoma cells triggered the interest of 
cancer researchers (Abe et al. 1981; Colston et al. 1981). Since then, numerous observations 
have indicated a much broader range of action for 1,25(OH)2D3, including the regulation of 
cell differentiation, proliferation, apoptosis, invasion and angiogenesis in several types of 
tumour cells and animal models of cancer (Ordoñez-Moran et al 2005; Deeb et al 2007; 
Krishnan and Feldman 2011). These 1,25(OH)2D3 actions suggest a potential therapeutic role 
against hyperproliferative disorders such as cancer. Nevertheless, the use of 1,25(OH)2D3 is 
restricted by its hypercalcemic effect at therapeutic doses. This can be putatively overcome by 
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the use of analogues that retain the antitumoural action but have less calcemic effect. 
Currently, there are numerous clinical trials ongoing using 1,25(OH)2D3 or its analogues, 
alone or in combination with other drugs, against several neoplasias (www.clinicaltrials.gov) 
(Deeb et al. 2007). 
 
Vitamin D and colon cancer: observational and epidemiological studies 
According to the International Agency for Research on Cancer (IARC) of the World Health 
Organization (WHO), about 12.7 million cancer cases and 7.6 million cancer deaths 
worldwide occurred in 2008. Colorectal cancer (CRC) is the third most frequent malignancy 
and the fourth leading cause of death from cancer worldwide, with 1,233,000 cases diagnosed 
and 608,000 deaths in 2008. 
The role of vitamin D in CRC prevention was first hypothesized by Frank and Cedric 
Garland based on ecological studies (Garland and Garland 1980). These authors proposed that 
the inverse relation between solar radiation (latitude) and CRC mortality and incidence in 
USA might be due to vitamin D synthesis. Later, the same authors reported an inverse 
association between vitamin D status and CRC in the USA (Garland et al. 1989). Since then, 
numerous studies have addressed the relationship between vitamin D status and colorectal 
adenoma and carcinoma incidence or mortality (Platz et al. 2000; Wu et al. 2007; Gandini et 
al. 2011). However, the integration and the overall analysis of all epidemiological studies is 
complex and thwarted by the fact that many of these studies do not take into account 
endogenous vitamin D production from sun exposure and are limited by measurement error 
from the various dietary assessment methods and food composition tables used to calculate 
dietary intake. Such limitations can be overcome by measuring circulating 25(OH)D 
concentration, a biomarker that provides an overall estimate of vitamin D status (both from 
endogenous production and from dietary intake).  
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The substantial body of literature that examines the relationship between 25(OH)D level 
and CRC risk generally supports an inverse association. A prospective study in the USA with 
16,818 participants found that CRC mortality was inversely related to serum 25(OH)D level 
(Freedman et al. 2007). A similar association was obtained in a case-control study that 
included an ethnically diverse population of Japanese, Latino, African-American, Caucasian 
and Native Hawaiian participants (Woolcott et al. 2010). Accordingly, a large observational 
nested case-control study (520,000 participants from 10 Western European countries) 
conducted within the European Prospective Investigation into Cancer and Nutrition concluded 
that there is a strong inverse association between 25(OH)D concentration and CRC (Jenab et 
al. 2010). A recent meta-analysis of 35 independent studies confirmed a consistent inverse 
relationship between serum 25(OH)D levels and CRC risk (Gandini et al. 2011). Ma et al. 
(Ma et al. JCO 2011) conducted a systematic review of 18 prospective studies assessing the 
association of vitamin D intake or serum levels of 25(OH)D and the risk of CRC in 
approximately 1,000,000 individuals and found an inverse correlation between CRC risk and 
both serum 25(OH)D and vitamin D intake. 
Accepting the problems of using different approaches and techniques to measure vitamin D 
status, the population diversity and the potential presence of confounding factors, the 
consistency of the association between vitamin D status and CRC risk indicates a causal 
association (Giovannucci 2010). Accordingly, the IARC stated that the epidemiological 
evidence for a r between serum 25(OH)D levels and the incidence of CRC is consistent and 
persuasive. However, such a causal relationship awaits large, adequate prospective clinical 
trials (IARC 2008).  
 
Antitumoural actions of 1 ,25-dihydroxyvitamin D3 in colorectal cancer cells 
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CRC arises as a consequence of the progressive accumulation of genetic and epigenetic 
alterations that induce the transformation and malignant progression of normal colonic 
epithelial cells. The initial genetic change in most colorectal adenomas, the earliest step in 
CRC, is the somatic mutation in the tumour suppressor gene APC (or, to a lesser extent, 
AXIN2 or CTNNB1/ -catenin genes). Each of these mutually exclusive mutations leads to 
aberrant activation of the canonical Wnt/ -catenin signalling pathway (Clevers 2006 Cell; 
Klaus and Birchmeier 2008 Nat Rev Cancer). In addition, a large proportion of adenomas 
carry activating mutations in K-RAS or B-RAF, whereas inactivating mutations in the 
transforming growth factor (TGF)-  pathway (mainly in SMAD2, SMAD4 or TGFBR2) confer 
additional malignant features to adenoma cells (Markowitz and Bertagnolli 2009 NEJM). The 
inactivation of the TP53 tumour suppressor gene matches the adenoma-carcinoma transition 
in around 50% of CRC tumours (Iacopetta 2003). The molecular mechanisms of carcinoma 
progression and the acquisition of metastatic ability remain to be fully elucidated, However, 
recent studies indicate that the epithelial-mesenchymal transition (EMT) endows epithelial 
cells with the capacity to invade the surrounding tissue and then to migrate to distant organs 
(Thiery et al. 2009; Chaffer and Weinberg 2011). 
Numerous studies have shown that the antitumoural action of 1,25(OH)2D3 in CRC relies 
on several mechanisms at the cellular level, such as inhibition of cell proliferation, 
sensitization to apoptosis, induction of epithelial differentiation and cell detoxification 
metabolism, and inhibition of angiogenesis (Figure 1). The combined effect of these 
mechanisms, in a cell-type- and cell-context-dependent manner, may determine the 
antitumoural action of 1,25(OH)2D3 (Lamprecht and Lipkin 2003; Deeb et al. 2007; Larriba et 
al. 2008 Capitulo libro; Krishnan and Feldman 2011 Ann Rev Pharmacol Toxicol). A detailed 
list of the most important 1,25(OH)2D3 target genes in human CRC cells and their role in the 




The growth-inhibitory effect of 1,25(OH)2D3 on CRC cells results from the accumulation of 
cells in the G0/G1 phase of the cell cycle. 1,25(OH)2D3 induces the expression of the cyclin-




, and represses that of cyclin A and cyclin F 
(Evans et al. 1999 Int J Oncol; Gaschott et al. 2002 BBRC; Pálmer et al. 2003; Fernández-
García et al. 2005). A recent report by Liu et al. (Int J Cancer 2010) indicates that the 
induction of p21
CIP1
 and the inhibition of proliferation by 1,25(OH)2D3 in CRC cell lines is 
dependent on the expression of the calcium-sensing receptor, which is in turn induced by 
1,25(OH)2D3 (Chakrabarty et al., 2005). 1,25(OH)2D3 also induces the expression of the 
growth-arrest and DNA damage 45  (GADD45A) gene (Pálmer et al. 2003), which is 
involved in cell cycle arrest after DNA damage and is required for the maintenance of 
genomic stability. In addition, 1,25(OH)2D3 regulates many other genes related to 
proliferation, including c-MYC, c-FOS and c-JUN (Pálmer et al. 2001; Pálmer et al. 2003; 
Meyer et al 2012 Mol Endocrinol). The c-MYC oncogene is deregulated and overexpressed in 
most cancers, and its downregulation by 1,25(OH)2D3 occurs directly, via multiple VDREs 
located in the promoter and intragenic regions, and indirectly, by increasing the expression 
and promoting the binding of intermediate proteins to regulatory regions of the gene (Pan Q et 
al. 1996 Endocrinology; Pan and Simpson 1999 J Biol Chem; Toropainen S et al. 2010 J Mol 
Biol; Meyer et al., 2011). As c-MYC is a target of the Wnt/ -catenin pathway, another indirect 
mechanism of downregulation of this gene by 1,25(OH)2D3 is the antagonism of this pathway 




Apoptosis sensitization by 1,25(OH)2D3 in colorectal adenoma and carcinoma cells involves 
the upregulation of the pro-apoptotic protein BAK and the downregulation of the nuclear anti-
apoptotic protein BAG-1 (Díaz et al. 2000; Barnes et al. 2005). The effect of 1,25(OH)2D3 on 
the expression of other pro-apoptotic (BAX) or anti-apoptotic (BCL-2, BCL-XL) proteins, 
which are regulated by 1,25(OH)2D3 in other cell systems, is not clear in CRC, and appears to 
be cell-specific (Díaz et al. 2000; Hansen et al. 2001). In addition, 1,25(OH)2D3 induces the 
expression of G0S2 (Pálmer et al. 2003), a mitochondrial protein that interacts with BCL-2 
and induces apoptosis in CRC cells by preventing BCL-2 from forming anti-apoptotic 
heterodimers with BAX (Welch C et al. 2009 Cancer Res). Although previous reports 
indicated that the apoptosis potentiated by 1,25(OH)2D3 does not require an intact TP53 
tumour suppressor gene (Díaz et al. 2000; Hansen et al. 2001), a recent study by Stambolsky 
et al. (Cancer Cell 2010) has revealed that mutant p53 protein interacts with VDR and 
modulates the transcriptional activity of 1,25(OH)2D3 leading to the increase of the expression 
of survival-promoting genes and the decrease of that of pro-apoptotic genes, thus converting 
1,25(OH)2D3 into an anti-apoptotic agent. In CRC cells, 1,25(OH)2D3 promotes sensitivity to 
the chemotherapeutic agent 5-fluorouracil by downregulating the expression and the 
transcriptional activity of survivin, an anti-apoptotic protein, and that of thymidylate synthase, 
an enzyme involved in DNA de novo synthesis and the molecular target of 5-fluorouracil (Liu 
G et al. 2010 Int J Cancer). Moreover, in an in vitro model developed to evaluate the crosstalk 
between tumour-associated macrophages and CRC cells, 1,25(OH)2D3 restores the sensitivity 
of CRC cells to TRAIL-induced apoptosis by interfering with the release of IL-1  by 




1,25(OH)2D3 has specific and multiple prodifferentiation effects in CRC cells. It increases the 
expression and/or activity of several brush border enzymes, such as alkaline phosphatase and 
maltase, and enhances the formation of microvilli (Brehier and Thomasset 1988 J Steroid 
Biochem; Giuliano AR et al. 1991 Arch Biochem Biophys; Halline AG et al. 1994; Díaz et al. 
2000). In addition, 1,25(OH)2D3 increases the expression of several components of cell 
adhesion structures that are essential for the maintenance of the epithelial phenotype: (i) 
occludin, zonula occludens (ZO)-1 and -2, and claudin-2 and -12 in tight junctions (Pálmer et 
al. 2001; Fujita H 2008 Mol Biol Cell); (ii) E-cadherin in adherens junctions (Pálmer et al. 
2001); and (iii) plectin in hemidesmosomes (Pálmer et al. 2003). Moreover, 1,25(OH)2D3 
induces the expression of components or proteins associated with the actin cytoskeleton and 
intermediate filaments such as keratin-13, vinculin, and filamin A (Pálmer et al. 2001; Pálmer 
et al. 2003). Filamin A has been implicated in cell motility, adhesion, and invasion 
(Nakamura et al. Cell Adh Migr 5, 160-169, 2011). However, novel functions of filamin A 
have recently been described within the cell nucleus, such as the regulation of nuclear shape 
during EMT and of DNA double-strand break repair (Yue J, Wang Q et al. 2009 Cancer Res; 
Gay O et al 2011 PNAS). 
 
Angiogenesis 
The angiogenic capacity of CRC cells may be affected by 1,25(OH)2D3, as it represses the 
expression and transcriptional activity of hypoxia-inducible factor (HIF)-1, a key transcription 
factor involved in hypoxia-induced angiogenesis (Ben-Shoshan et al. 2007 Mol Cancer Ther). 
In addition, 1,25(OH)2D3 regulates the expression of vascular endothelial growth factor 
(VEGF) and thrombospondin-1 (TSP-1), two major opposing factors that control tumour 
angiogenesis, leading to a balanced change in the angiogenic potential of SW480-ADH cells 
(Fernández-García et al. 2005). Further, 1,25(OH)2D3 strongly represses DICKKOPF-4 
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(DKK-4), a weak Wnt antagonist that promotes invasion and angiogenesis in cultured CRC 
cells and is upregulated in colon tumours (Pendás-Franco et al. 2008). 
 
Detoxification 
Intestinal epithelial cells express a variety of enzymes involved in the detoxification and 
metabolism of xenobiotics from dietary sources and of deleterious endobiotic compounds that 
may contribute to CRC development. Phase I enzymes, most of which belong to the 
cytochrome P450 (CYP) superfamily, initiate the enzymatic detoxification of these 
compounds by oxidation, hydrolysis or reduction (Kaminsky and Zhang 2003 Drug Metab 
Dispos). In CRC cells, 1,25(OH)2D3 induces the expression of CYP3A4, the member of the 
CYP superfamily most expressed in the intestine (Thummel et al. 2001 Mol Pharmacol; 
Thompson et al. 2002 Biochem Biophys Res Com; Pfrunder A et al. 2003 J Pharm 
Pharmacol). Likewise, several members of the CYP2C subfamily contain VDREs in their 
promoters and are regulated by 1,25(OH)2D3 in hepatic tissues. As CYP2C is the second most 
abundant CYP subfamily in the human intestine, its putative regulation by 1,25(OH)2D3 in the 
intestine could be highly relevant (Drocourt L et al. 2002 J Biol Chem; Chen and Goldstein 
2009 Curr Drug Metab). 
Phase II enzymes conjugate different charged groups to the compounds previously 
modified by phase I enzymes, which increases their solubility in water and facilitate their 
excretion (Kaminsky and Zhang 2003 Drug Metab Dispos). In CaCo-2 cells, 1,25(OH)2D3 
activates the transcription of SULT2A1, a phase II sulphotransferase that acts preferentially 
on hydroxysteroids and cholesterol-derived sterol bile acids, but may also modify several 
drugs and other xenobiotics (Echchgadda I et al. 2004 Mol Pharmacol). 
In addition, 1,25(OH)2D3 regulates the expression of several transporters responsible for 
the efflux of phase II conjugates to the extracellular medium. One of them is the drug efflux 
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pump multidrug resistance protein (MDR)-1, which is located in the enterocyte apical 
membrane (Pfrunder A et al. 2003 J Pharm Pharmacol; Aiba T et al. 2005 Drug Metab 
Pharmacokinet, Fan et al. 2009 J Pharmacol Exp Ther). 1,25(OH)2D3 also modulates the 
expression of members of the multidrug resistance-associated protein (MRP) family, which 
are involved in the transport of conjugated and unconjugated bile acids, and also in that of 
glutathione and sulphate conjugates (McCarthy et al. 2005 J Biol Chem; Fan et al. 2009 J 
Pharmacol Exp Ther). 
Thus, 1,25(OH)2D3 has a wide-ranging effect on the expression of several proteins 
involved in intestinal detoxification, which is consistent with a preventive and therapeutic 
action of this hormone against CRC. 
 
Interference with the Wnt/ -catenin pathway and interplay with other signalling pathways 
1,25(OH)2D3 interferes with several signalling pathways, which may partially mediate its 
antitumoural effects. Results from our group and others have demonstrated that 1,25(OH)2D3 
inhibits the Wnt/ -catenin pathway and the activation of its target genes in CRC cells, which 
contributes to the inhibition of cell proliferation and to the maintenance of the differentiated 
phenotype (Pálmer et al., 2001; González-Sancho et al. libro vitD 2011 Feldman, review). 
1,25(OH)2D3 inhibits the Wnt/ -catenin pathway through several mechanisms. First, it rapidly 
increases the amount of VDR bound to -catenin, thus reducing the interaction between -
catenin and the transcription factors of the TCF/LEF family and leading to the repression of 
its target genes (Pálmer et al. 2001). Shah et al. (2006) confirmed the VDR/ -catenin 
interaction and characterized the protein domains involved, while Egan et al. (2010) reported 
that wild-type APC enhances the inhibition of -catenin/TCF transcriptional activity by 
1,25(OH)2D3. Second, 1,25(OH)2D3 induces -catenin nuclear export linked to E-cadherin 
accumulation at the plasma membrane adherens junctions (Pálmer et al. 2001). Third, it 
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induces the expression of DKK-1, an extracellular Wnt inhibitor (Aguilera et al. 2007). In 
addition, 1,25(OH)2D3 impedes the production of IL-1  by THP-1 monocytic leukemia cells 
and, if extrapolated to tumour-associated macrophages, this would represent another 
mechanism of inhibition of -catenin/TCF-dependent gene activation in CRC cells, as IL-1  
inhibits -catenin phosphorylation and labeling for degradation by GSK-3  (Kaler et al. 
Oncogene 2009). Thus, 1,25(OH)2D3 exerts a complex set of regulatory actions leading to the 
inhibition of the Wnt/β-catenin pathway. As this pathway is aberrantly activated in most 
adenomas and colorectal tumours and is considered the main driving force in this neoplasia, 
its inhibition is probably crucial for the antitumoural action of 1,25(OH)2D3 in CRC. 
Additionally, 1,25(OH)2D3 sensitizes CRC cells to the growth inhibitory action of TGF-  
by upregulating the expression of its type I receptor (TGFBR1) (Chen et al. 2002). Moreover, 
1,25(OH)2D3 inhibits the stimulation of cell proliferation by epidermal growth factor (EGF) 
via the reduction of EGF receptor (EGFR) expression and the induction of its internalization 
upon ligand binding (Tong et al. 1999). 1,25(OH)2D3 may also inhibit EGFR activity by 
inducing the expression of E-cadherin (Pálmer et al 2001) and by repressing that of 
SPROUTY-2 (Barbáchano et al 2010, see below), which are respectively negative and 
positive regulators of EGFR activity (Andl CD and Rustgi AK 2005 Cancer Biol Ther, 
Cabrita and Christofori 2008). Likewise, 1,25(OH)2D3 interferes with the growth-stimulatory 
effect of insulin growth factor (IGF)-II through the inhibition of IGF-II secretion and the 
modulation of the expression of several genes encoding IGF binding proteins (IGFBP) (Oh et 
al. 2001, Pálmer et al. 2003). 
 
1 ,25-dihydroxyvitamin D3 target genes in colorectal cancer cells 
The development of high-throughput techniques for gene expression profiling, such as 
microarrays, has allowed a more detailed study of 1,25(OH)2D3 effects in the transcriptome of 
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cancer cells (reviewed in Kriebitzsch et al. 2009 Anticancer Res). We and others (Pálmer 
2003; Wood et al. 2004 Physiol Genomics) performed oligonucleotide microarrays in CRC 
cells treated with 1,25(OH)2D3. Our results showed that around two thirds of 1,25(OH)2D3 
target genes are upregulated, while a third of these genes are downregulated after 
1,25(OH)2D3 treatment. A high proportion of the regulated genes are related to transcription, 
cell adhesion and metabolism, although genes related to many different cell functions were 
also found (Pálmer et al 2003). In the past decade, our laboratory has dedicated much effort to 
characterizing the role of several of these genes in the antitumoral action of 1,25(OH)2D3 in 
CRC. 
One of the genes regulated by 1,25(OH)2D3 in our transcriptomic analysis was CST5, 
encoding cystatin D, an inhibitor of cysteine proteases of the cathepsin family. We validated 
the strong induction of cystatin D by 1,25(OH)2D3 and found that it mediates the 
antiproliferative and prodifferentiation effects of 1,25(OH)2D3 in CRC cells (Álvarez-Díaz et 
al 2009). Cystatin D regulation by 1,25(OH)2D3 also occurs in xenografted mice treated with 
the 1,25(OH)2D3 analogue EB1089/Seocalcitol, and a direct correlation between cystatin D 
and VDR protein levels was observed in human CRC biopsies, suggesting that 1,25(OH)2D3 
also regulates cystatin D in vivo (Álvarez-Díaz et al 2009). In addition, ectopic cystatin D 
inhibits proliferation, migration and anchorage-independent growth of cultured CRC cells and 
growth of xenografted tumours in mice. Moreover, cystatin D expression is downregulated 
during colorectal tumourigenesis and is associated with tumour dedifferentiation. All together, 
these data led us to propose CST5 as a candidate tumour suppressor gene in CRC (Álvarez-
Díaz et al 2009). The mechanism by which this protease inhibitor mediates its actions is not 
fully understood. Experiments using mutant cystatin D proteins with reduced antiproteolytic 
activity indicate that at least some of its antitumour effects may be independent of cathepsin 
inhibition (Álvarez-Díaz et al 2009). In line with this, 1,25(OH)2D3 regulates a number of 
 18 
genes related to the protein degradation machinery, such as proteases, other protease 
inhibitors, and components of the ubiquitin-proteasome system (Álvarez-Díaz et al. 2010 Cell 
Cycle). 
SPRY-2 is another gene shown by transcriptomic assays to be regulated by 1,25(OH)2D3 
(5.6-fold repression at 4 h of treatment) (Pálmer et al., 2003). SPRY-2 encodes SPROUTY-2, 
an intracellular modulator of EGFR and other growth factor tyrosine kinase receptors 
involved in the regulation of cell growth, migration and angiogenesis (Cabrita and Christofori, 
2008). SPROUTY-2 strongly inhibits the intercellular adhesion induced by 1,25(OH)2D3, and 
gain- and loss-of-function experiments showed that SPROUTY-2 and E-cadherin repress 
reciprocally in CRC cell lines and have opposite actions on cell differentiation (Bárbachano et 
al. 2010). Accordingly, the expressions of SPROUTY-2 and E-cadherin are mutually 
exclusive in xenografted tumours and correlate inversely in human CRC biopsies, where 
SPROUTY-2 is upregulated in undifferentiated high-grade tumours and at the invasive front 
of low-grade carcinomas (Barbáchano et al., 2010). Therefore, SPROUTY-2 is inhibited by 
1,25(OH)2D3 and is a potential novel marker of malignancy and a 
pharmacological/therapeutic target in CRC.  
Several candidate 1,25(OH)2D3 target genes encode for proteins implicated in epigenetic 
regulation of gene expression. We have recently reported that 1,25(OH)2D3 induces the 
expression of the JMJD3 gene (Pereira et al. 2011), which codes for a histone demethylase of 
the tri-methyl repressive mark on lysine 27 of histone H3, and which may have an important 
tumour suppressor function (De Santa et al 2007; Agger et al 2009). JMJD3 partially mediates 
the prodifferentiation, antiproliferative and gene regulatory actions of 1,25(OH)2D3, and also 
its antagonism of the Wnt/ -catenin pathway (Pereira et al. 2011). Moreover, JMJD3 
depletion upregulates the expression of EMT inducers and mesenchymal markers, while it 
downregulates that of epithelial proteins. Importantly, and in line with data in cultured cells, 
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the expression of JMJD3 RNA was lower in tumour tissue than in normal tissue in a 56% of 
human colorectal tumours and directly correlates with that of VDR (Pereira et al. 2011). 
Recent data indicate that 1,25(OH)2D3 modulates the expression of several genes coding for 
histone demethylases of the Jumonji C domain and lysine-specific demethylase families 
(Pereira et al. 2011 in press/submitted). These findings link chromatin epigenetic regulation 
with the transcriptional activity of 1,25(OH)2D3. 
The new generation of ChIP-Seq studies mentioned mentioned are expected to contribute 
to our understanding of 1,25(OH)2D3 actions on a genome-wide scale, and to the 
identification of its target genes. In their work, Meyer et al. (2012) report new genes activated 
by 1,25(OH)2D3 in LS180 colon cancer cells, such as several members of the peptidylarginine 
deiminase family, a class of enzymes that convert histone methylated residues of arginine to 
citrulline (Klose and Zhang 2007), thus expanding the number of epigenetic modifiers that are 
regulated by 1,25(OH)2D3 in CRC cells. 
Proteomic approaches have also identified 1,25(OH)2D3-regulated proteins in CRC cells. 
Our laboratory has used 2D-DIGE electrophoresis combined with MALDI-TOF-TOF mass 
spectrometry to identify nuclear proteins regulated by 1,25(OH)2D3 in SW480-ADH cells 
(Cristobo et al. 2011 J Prot). Interestingly, several of these proteins are involved in the 
regulation of the spliceosome machinery, suggesting a role of 1,25(OH)2D3 in alternative 
splicing, which is frequently altered in cancer (Miura K et al 2011 Cancer Sci; David and 
Manely 2011 Genes Dev). In addition, 1,25(OH)2D3 also regulates the expression of a few 
cytoskeletal and actin-binding proteins (ezrin, radixin, coronin 1C), some of which perform 
transcription-related functions in the cell nucleus in addition to modulating cell morphology 
and adhesion (Cristobo et al. 2011 J Prot). 
 
Mechanisms of resistance to 1 ,25-dihydroxyvitamin D3 action in colorectal cancer 
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CRC cell responsiveness to 1,25(OH)2D3 depends mainly on the expression of VDR and on 
the bioavailability of 1,25(OH)2D3 within the cell. The intracellular level of 1,25(OH)2D3 is 
determined by the circulating levels of 25(OH)D3 and 1,25(OH)2D3, and by the activity of 
CYP27B1 and CYP24A1 within the cell. CYP27B1 expression and activity are upregulated at 
early stages of colorectal tumourigenesis and drastically decreased in advanced CRC, while 
those of CYP24A1 are overexpressed in colorectal carcinomas. These changes lead to 
attenuated 1,25(OH)2D3 synthesis and accelerated 1,25(OH)2D3 catabolism in advanced CRC, 
causing resistance to 1,25(OH)2D3 (Bareis et al 2001 Biochem Biophys Res Commun; Cross 
et al 2001 Steroids; Bises et al 2004 J Histochem Cytochem). 
Several studies have shown that VDR is expressed by normal and certain tumour colon 
epithelial cells (Sheinin 2000 Virchows Arch; González-Sancho et al 2006; Modica S 
Gastroenterology 2010) and is associated with a high degree of cell differentiation (Zhao and 
Feldman 1993 Endocrinology; Shabahang M et al. 1993 Cancer Res). VDR expression is 
enhanced in early stages of colorectal tumourigenesis (adenomas, polyps), whereas it 
decreases in advanced stages (Sheinin 2000 Virchows Arch; Cross HS et al 2001; Larriba and 
Muñoz 2005; Matusiak et al. 2005; Anderson et al 2006). Accordingly, elevated VDR 
expression is associated with high tumour differentiation, absence of node involvement, and 
good prognosis in CRC (Cross HS et al 1996; Evans et al 1998). 
VDR downregulation causes unresponsiveness to 1,25(OH)2D3 and failure of the therapy 
with 1,25(OH)2D3 or its analogues. For this reason, our group has searched for mechanisms to 
explain the loss of VDR in advanced CRC. We found that SNAIL1, a repressor of E-cadherin 
and a strong EMT inducer, represses the expression of VDR and blocks 1,25(OH)2D3 
antitumoural actions in CRC cells in culture and such cells xenografted in mice (Palmer et al 
2004; Larriba et al 2007). Additionally, SNAIL1 is upregulated in approximately 60% of 
colorectal tumours and is associated with VDR downregulation (Pálmer et al 2004; Peña et al 
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2005; Peña et al 2006). In addition to SNAIL1, its family member SNAIL2 (but not other 
EMT inducers such as ZEB1, ZEB2, TWIST1 or E47) also represses VDR expression and 
blocks 1,25(OH)2D3 action in CRC cells (Larriba et al 2009). Moreover, SNAIL1 and 
SNAIL2 show an additive repressive effect on VDR expression in cultured cells and in 
colorectal tumours (Larriba et al 2009; Larriba et al 2010 JSMB). Thus, it is likely that 
efficient VDR repression during CRC progression requires the expression of both SNAIL1 
and SNAIL2, and that their expression in colorectal tumours could be used to identify patients 
who are likely to benefit from therapy with 1,25(OH)2D3 or its analogues. 
 
Antitumoural action of vitamin D in animal models of colorectal cancer 
Results obtained in several types of studies using experimental animals support a protective 
and therapeutic action of vitamin D against CRC. Administration of a western-style diet (high 
in fat and low in vitamin D and calcium) generates colonic crypt hyperplasia and colon 
dysplasia in wild-type mice, and increases the incidence of preneoplastic lesions in various 
preclinical mouse models of intestinal tumourigenesis. These effects are suppressed upon diet 
supplementation with calcium and vitamin D (reviewed in Lamprecht and Lipkin 2003, 
Ordóñez-Morán et al 2005). 
Human tumour cells implanted subcutaneously into immunosuppressed mice (xenografts) 
are commonly used as an in vivo approach in preclinical anticancer drug development. 
Numerous studies have shown that 1,25(OH)2D3 and several analogues clearly reduce the 
growth of colorectal xenografts (reviewed in Ordóñez-Morán et al. 2005; Deeb et al. 2007; 
Kang et al. 2011 World J Gastro Oncology). Similar results were obtained using different 
chemical carcinogens (N-methyl-N-nitrosourea, azoxymethane and others) to generate 
colorectal tumours in mice or rats. The number of tumours generated after chronic treatment 
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with the carcinogens was reduced by the administration of 1,25(OH)2D3 or several of its 
analogues (reviewed in Ordóñez-Morán et al., 2005). 
Both 1,25(OH)2D3 and its less calcemic derivative 1,25(OH)2-16-ene-19-nor-24-oxo-D3 
reduce tumour load (the sum of all polyp areas) in Apc
min/+
 mice, a mouse model of intestinal 
carcinogenesis that carries a mutated allele of the tumour suppressor gene Apc and 
spontaneously develops multiple neoplasias throughout the intestinal tract. Xu et al. (2010) 
confirmed these results and also found that treatment with 1,25(OH)2D3 or two of its 
analogues increases the expression of E-cadherin, inhibits that of c-myc and reduces -catenin 
nuclear levels in the small intestine and colon of Apc
min/+
 mice. However, a recent study by 
Irving et al. (2011) has shown that treatment with 25(OH)D3 or two 1,25(OH)2D3 analogues 
did not affect intestinal tumour development in the Apc
Pirc/+
 rat or in the Apc
min/+
 mouse 
models in the absence or in the presence of the colonic tumour inducer dextran sodium 
sulphate (Irving et al. 2011). As the authors comment, it is however possible that the length of 
treatment with the vitamin D compounds, or the putative loss of Vdr expression in the 
tumours might have influenced the results of the study (Irving et al. 2011). 
Genetically-modified mice have also been used to study the effects of the disruption of 
VDR expression on colorectal tumourigenesis. Vdr-deficient mice do not show a spontaneous 
increase in cancer but are more prone to oncogene- or carcinogen-induced tumours (Bouillon 
et al. 2008 Endocr Rev). These animals display colonic crypt hyperproliferation, and 
increased levels of DNA damage and oxidative stress in the intestine (Kallay E et al 2001 





 mice in order to evaluate the consequences of Vdr deficiency on the initiation 
and development of intestinal cancer (Larriba et al., 2011; Zheng et al., 2011). These studies 














 mice also show higher activation of the Wnt/ -catenin pathway 
and an increase in the number of colonic aberrant crypt foci (Larriba et al., 2011). 
 
Human studies: clinical and molecular data 
Few large-scale cancer intervention trials on vitamin D treatment in human CRC patients have 
been reported. The first of these was a randomized, double-blind, placebo-controlled trial of 
2,686 individuals (65-85 yr of age) receiving 100,000 IU vitamin D3 or placebo every 4 
months (~833 IU/d). This study did not find any significant effect of vitamin D3 
supplementation on CRC incidence or mortality after 5 years (Trivedi et al. 2003 BMJ). 
Accordingly, another randomized, double-blinded, placebo-controlled trial performed by the 
US Women’s Health Initiative, including 36,282 postmenopausal women (50-79 yr of age) 
who were treated with 400 IU/d vitamin D3 + 1 g/d calcium vs placebo, failed to find any 
effect of the treatment on CRC incidence (Wactawski-Wende et al. New England J Med 
2006). However, the study had serious drawbacks that challenge its validity: the low amount 
of vitamin D3 used did not increase the circulating 25(OH)D3 levels, the degree of patient 
adherence to the treatment was low, and the follow-up period was short (7 years) (Wactawski-
Wende et al. New England J Med, 2006). Still, re-analysis of the data showed that concurrent 
estrogenic therapy increased CRC risk and that the treatment with vitamin D3 + calcium was 
beneficial in its absence (relative risk, RR 0.71; 95% confidence interval, 95% CI 0.46-1.09) 
(Ding et al. Int J Cancer 2008). The third study with published results was a smaller trial 
performed in Nebraska (USA) with 1,179 postmenopausal women (mean age 67 yr) who were 
treated with 1,100 IU/d vitamin D3 + 1.4-1.5 g/d calcium vs calcium alone for 4 years (Lappe 
et al. 2007 Am J Clin Nutr). Treatment with vitamin D3 + calcium reduced total cancer 
incidence (RR 0.40; 95% CI 0.20-0.82), including CRC, particularly if the first-year cases 
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were not considered. However, the low number of CRC cases reduces the validity of the study 
(Lappe et al. 2007 Am J Clin Nutr). 
At the molecular level, Holt et al. (2006) showed that combined daily supplementation of 
11 patients with vitamin D3 (400 IU) and calcium (1.5 g) for six months reduced the 
proliferation of colonic flat mucosa and polyps, increased the expression of BAK and 
diminished that of the CRC-associated mucin MUC5AC when compared to the placebo group 
(8 patients). In a series of recent papers, Fedirko et al. reported that 800 IU/d vitamin D3 
and/or 2 g/d calcium (in 92 patients with at least one adenoma, six months treatment) 
increased BAX and p21
CIP1
 expression in colorectal crypts (Fedirko et al Cancer Prev Res 
2009; Fedirko et al. Cancer Epidemiol Biomarkers Prev 2009). These authors also observed a 
decreased labelling of the DNA oxidation marker 8-OH-dG (induced only by vitamin D3 or 
calcium alone, but not by the combination) and reduced expression of the marker of long-term 
proliferation hTERT in the upper part of the crypt (only in the vitamin D3 + calcium group) 
(Fedirko et al. Cancer Epidemiol Biomarkers Prev 2009; Fedirko et al., Cancer Epidemiol 
Biomarkers Prev 2010). In addition, the group treated with vitamin D3 alone showed a 
reduction in the expression of the pro-inflammatory cytokines TNF- , IL-6, IL-1  and IL-8, 
and the pro-inflammatory marker C-reactive protein (Hopkins MH et al. Cancer Prev Res 
2011). 
Clearly, there is a need for large and well-designed randomized, double-blind, placebo-
controlled clinical studies. Up to now, clinical trials have included mostly elderly people, 
frequently postmenopausal women, and so, they may not fully reveal the potential action of 
vitamin D. Additional problems are the lack of an optimal vitamin D3 dose to be used, its 
possible combination with other agents (calcium), and the long follow-up period that seems 
recommendable in the case of a disease such as CRC, which probably develops over one or 
two decades. One promising ongoing trial is the VITamin D and OmegA-3 TriaL (VITAL), a 
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study designed to investigate the role of high doses of vitamin D3 (2,000 IU/d), omega-3 fatty 
acids (1 g/d), and their combination on cancer and cardiovascular diseases in 20,000 initially 
healthy men and women aged 60 and 65 yr and older, respectively (Okereke and Manson 
libro azul, Nicholas J 2011 JNCI). In addition, a recent look at the US National Institutes of 
Health clinical trials website (http://clinicaltrials.gov) showed that more than 1,000 trials are 
currently underway to assess the effects of vitamin D compounds on cancer and other 
diseases. 
 
Conclusions and perspectives 
In summary, the vast majority of molecular and genetic data suggests a protective role of 
vitamin D against CRC, and epidemiological studies also indicate also that vitamin D 
deficiency is linked to high risk of this neoplasia. Globally, the results available on the loss of 
VDR expression and on the alteration of CYP27B1 and CYP24A1 levels during CRC 
progression support a role for vitamin D in the prevention and/or in the therapy of early stages 
rather than in the treatment of advanced cases of this neoplasia. 
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Figure 1. Summary of the antitumoural actions of 1 ,25-dihydroxyvitamin D3 in colorectal 
cancer cells. 1,25(OH)2D3 inhibits cell proliferation and angiogenesis, sensitizes to apoptosis, 




Table 1. 1 ,25-dihydroxyvitamin D3 antitumoural actions and target genes in human colorectal cancer cells 
Action Target gene Reference 
Proliferation p21
CIP1
 Evans et al. 1999, Gaschott et al. 2002 
 p27
KIP1
 Gaschott et al. 2002 
 Cyclin A Fernández-García et al. 2005 
 Cyclin F Pálmer et al. 2003 
 GADD45A Pálmer et al. 2003 
 c-MYC Pálmer et al. 2001, Meyer et al. 2012 
 c-FOS Meyer et al. 2012 
 c-JUN Pálmer et al. 2003 
 TGFBR1 Chen et al. 2002 
 EGFR Tong et al. 1999 
 IGFBP6 Oh et al. 2001 
 CST5 Álvarez-Díaz et al. 2009 
 JMJD3 Pereira et al. 2011 
Apoptosis BAK Díaz et al. 2000 
 BAG-1 Barnes et al. 2005 
 G0S2 Pálmer et al. 2003 
 Survivin Liu et al. 2010 
 Thymidylate synthase Liu et al. 2010 
Differentiation Alkaline phosphatase Giuliano et al. 1991, Halline et al. 1994, Díaz et al. 2000 
 Maltase Brehier & Thomasset 1988 
 Occludin Pálmer et al. 2001 
 ZO-1 Pálmer et al. 2001 
 ZO-2 Pálmer et al. 2001 
 Claudin-2 Fujita et al. 2008 
 Claudin-12 Fujita et al. 2008 
 E-cadherin Pálmer et al. 2001 
 Plectin Pálmer et al. 2003 
 Keratin-13 Pálmer et al. 2003 
 Vinculin Pálmer et al. 2001 
 Filamin A Pálmer et al. 2003 
 CST5 Álvarez-Díaz et al. 2009 
 SPRY-2 Barbáchano et al. 2010 
 JMJD3 Pereira et al. 2011 
Angiogenesis HIF-1 Ben-Shoshan et al. 2007 
 VEGF Fernández-García et al. 2005 
 TSP-1 Fernández-García et al. 2005 
 DKK-4 Pendás-Franco et al. 2008 
Detoxification CYP3A4 Thummel et al. 2001, Thompson et al. 2002, Pfrunder et al. 2003 
 SULT2A1 Echchgadda et al. 2004 
 MDR-1 Pfrunder et al. 2003, Aiba et al. 2005, Fan et al. 2009 
 MRP2 Fan et al. 2009 
 MRP3 McCarthy et al. 2005 
 MRP4 Fan et al. 2009 
 
